依鲁替尼与Btk靶向风险。 - Suppr

Suppr

超能文献

Ibrutinib and a Btk-targeted risk.

作者信息

Woyach Jennifer A

机构信息

The Ohio State University Comprehensive Cancer Center.

出版信息

Blood. 2018 Nov 1;132(18):1869-1870. doi: 10.1182/blood-2018-08-865659.

DOI:10.1182/blood-2018-08-865659

PMID:30385492

Abstract

摘要

相似文献

Ibrutinib and a Btk-targeted risk.

Blood. 2018 Nov 1;132(18):1869-1870. doi: 10.1182/blood-2018-08-865659.

Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during phagocytosis.

Blood. 2018 Nov 1;132(18):1985-1988. doi: 10.1182/blood-2017-12-823393. Epub 2018 Jul 18.

High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma.

J Exp Clin Cancer Res. 2017 Sep 25;36(1):132. doi: 10.1186/s13046-017-0600-7.

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.

Oncotarget. 2017 Jun 13;8(24):39218-39229. doi: 10.18632/oncotarget.16836.

Activation of NF-κB and respiratory burst following Aspergillus fumigatus stimulation of macrophages.

Immunobiology. 2014 Jan;219(1):25-36. doi: 10.1016/j.imbio.2013.06.013. Epub 2013 Jul 4.

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.

Med Sci Monit. 2019 Oct 23;25:7951-7957. doi: 10.12659/MSM.916950.

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.

Oncotarget. 2015 Dec 8;6(39):42232-42. doi: 10.18632/oncotarget.6273.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

Blood. 2017 May 4;129(18):2519-2525. doi: 10.1182/blood-2017-01-761726. Epub 2017 Feb 24.

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7.

引用本文的文献

Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study.

Ann Intensive Care. 2023 Dec 6;13(1):123. doi: 10.1186/s13613-023-01219-5.

Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.

Int J Mol Sci. 2023 Jan 31;24(3):2645. doi: 10.3390/ijms24032645.

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Cancers (Basel). 2021 Jun 29;13(13):3240. doi: 10.3390/cancers13133240.

The robust and rapid role of molecular testing in precision fungal diagnostics: A case report.

Med Mycol Case Rep. 2020 Feb 13;27:77-80. doi: 10.1016/j.mmcr.2020.02.003. eCollection 2020 Mar.

Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature.

Med Mycol Case Rep. 2019 Dec 3;27:14-16. doi: 10.1016/j.mmcr.2019.12.005. eCollection 2020 Mar.

A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.

Med Mycol Case Rep. 2019 Dec 5;27:17-21. doi: 10.1016/j.mmcr.2019.12.007. eCollection 2020 Mar.

Bruton Tyrosine Kinase Inhibitors: Present and Future.

Cancer J. 2019 Nov/Dec;25(6):386-393. doi: 10.1097/PPO.0000000000000412.

How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Blood. 2019 Mar 21;133(12):1298-1307. doi: 10.1182/blood-2018-11-846808. Epub 2019 Jan 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验